Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
17. Oktober 2024 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients’ eyelids Demodex blepharitis is a significant eyelid disease that impacts...
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
05. März 2024 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease Demodex blepharitis impacts approximately 25...
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
24. August 2023 09:00 ET
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available...
Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers
08. Mai 2023 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis is a highly prevalent, yet often undiagnosed eyelid disease that impacts approximately 25 million eye care patients in the U.S. IRVINE, Calif., May 08, 2023 (GLOBE NEWSWIRE) --...
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
25. Oktober 2022 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the FDA for TP-03 Data from an investigator-initiated trial evaluating...
Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair
06. Oktober 2022 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Mr. Morrison brings over 40 years of financial and operational expertise in life sciences IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose...
Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis
29. September 2022 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis is a highly prevalent, yet often missed or misdiagnosed lid margin disease that impacts approximately 25 million eye care patients in the U.S. IRVINE, Calif., Sept. 29, 2022 ...
Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings
27. September 2022 12:00 ET
|
Tarsus Pharmaceuticals, Inc
Positive data to be presented at WCC VIII and AAO 2022 conferences in Chicago Tarsus recently submitted NDA to the FDA for TP-03 IRVINE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Tarsus...
Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting
05. Mai 2022 08:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting
26. April 2022 08:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...